Live tape
Top 8, mentions 7d15,627HTZ4,090 mentions▲ +0.09SPCX2,969 mentions▲ +0.07GOOGL2,266 mentions▲ +0.03SNDK2,017 mentions▲ +0.08NVDA1,353 mentions▲ +0.08MSFT1,084 mentions▲ +0.06SPY994 mentions▲ +0.07VOO854 mentions▲ +0.08

Equity · Healthcare

AGL

agilon health, inc. · NYSE

$96.95 +0.99% 1D Finazon · prior-day close · Aug 10, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$140 $60 13 May 10 Aug

The line runs $72 on 13 May through $96.95 on 10 August, on a scale from $60 to $140. Days the market did not trade hold the previous close, flat.

The chart above plots the price of AGL over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $72 on 13 May 2026 through $96.95 on 10 August 2026.

Market cap $1.6B
52-week range $7.90 – $129
Avg volume 95.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 11, 2026

AGL insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 1 Aug 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 10

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Aug 2026 Zamore Denise Chief Legal Officer Tax withheld 37 $3K
01 Jul 2026 Schwaneke Jeffrey A. Chief Financial Officer Tax withheld 2,311 $258K
02 Jun 2026 Battaglia Silvana Director Award 2,133
02 Jun 2026 MCKENZIE DIANA Director Award 2,133
02 Jun 2026 Mansukani Sharad Director Award 2,133
02 Jun 2026 McLoughlin Karen Director Award 2,133
02 Jun 2026 WILLIAMS RONALD A Director Award 2,133
02 Jun 2026 Wulf John William Director Award 2,133
01 Jun 2026 Zamore Denise Chief Legal Officer Tax withheld 485 $45K
24 May 2026 Gertsch Timothy Chief Accounting Officer Tax withheld 8 $1K

AGL reported financials

SEC EDGAR XBRL

AGL reported revenue of $5.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was −$391.3M.

Figure Reported Period
Revenue $5.9B 31 Dec 2025 fiscal year
Net income −$391.3M 31 Dec 2025 fiscal year
Total assets $1.6B 30 Jun 2026 at period end
Total equity incl. minority interest $227.5M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

AGL earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.04 $1.49B
31 Mar 2026 Q1 2026 $2.94 $1.42B
31 Dec 2025 FY 2025 $5.93B
30 Sep 2025 Q3 2025 $1.44B
30 Jun 2025 Q2 2026 $-6.31 $1.39B
31 Mar 2025 Q1 2026 $0.73 $1.53B
31 Dec 2024 FY 2024 $6.06B
30 Sep 2024 Q3 2024 $1.45B

Reported figures & scheduled dates · SEC EDGAR filings

AGL institutional holders

SEC Form 13F

5 of the 45 institutional funds we track reported a AGL position for the quarter ended 31 Mar 2026 — a combined $15.8M; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
AQR Capital Management New position 974,897 $7.7M
D. E. Shaw & Co. New position 742,218 $5.9M
Renaissance Technologies New position 149,043 $1.2M
Two Sigma Investments New position 99,352 $786K
Tudor Investment Corp New position 32,230 $255K
Marshall Wace Exited

Source: SEC EDGAR 13F filings

AGL fails-to-deliver

SEC CNS data

On 30 Jun 2026, 25 shares of AGL failed to deliver (about $3K) — the latest of at least 2 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 25 $3K <0.001%
29 Jun 2026 199 $24K 0.001%

Source: SEC fails-to-deliver (CNS) data